These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. High CD133 expression levels in gastrointestinal stromal tumors. Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307 [TBL] [Abstract][Full Text] [Related]
47. Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors. Hsu KH; Tsai HW; Lin PW; Hsu YS; Lu PJ; Shan YS World J Surg Oncol; 2014 Jun; 12():189. PubMed ID: 24947165 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235 [TBL] [Abstract][Full Text] [Related]
50. [Expression of MDR1 and KIT in imatinib-resistant gastrointestinal stromal tumor cells]. Liu JL; Qin J; Yao LQ; Hou YY; Sun YH; Shen KT; Su P Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Jul; 13(7):506-9. PubMed ID: 20658364 [TBL] [Abstract][Full Text] [Related]
51. Imatinib mesylate induces responses in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy. Fiorentini G; Bernardeschi P; Rossi S; Dentico P; Biancalani M; Giustarini G; Turrisi G J Cancer Res Ther; 2006; 2(2):68-71. PubMed ID: 17998678 [TBL] [Abstract][Full Text] [Related]
52. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment. Yeh CN; Chen TW; Liu FY; Jan YY; Chen MF Langenbecks Arch Surg; 2006 Nov; 391(6):615-21. PubMed ID: 17024483 [TBL] [Abstract][Full Text] [Related]
54. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives. Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778 [TBL] [Abstract][Full Text] [Related]
55. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460 [TBL] [Abstract][Full Text] [Related]
56. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Demetri GD Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386 [TBL] [Abstract][Full Text] [Related]
57. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. Blanke CD; Huse DM J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355 [TBL] [Abstract][Full Text] [Related]
58. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
59. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM Cancer Res; 2005 Nov; 65(21):9633-6. PubMed ID: 16266981 [TBL] [Abstract][Full Text] [Related]
60. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]